Twist Bioscience Corp vs Vanguard International High Dividend Yield ETF — how do they compare? Twist Bioscience Corp trades at $124.24 (market cap $7.72B), while Vanguard International High Dividend Yield ETF trades at $104.53. Which is the better fit depends on your goals.
| TWST | VYMI | |
|---|---|---|
Market Cap | $7.72B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $124.88 | $105.05 |
52-Week Low | $24.16 | $82.92 |
Enterprise Value | $7.65B | — |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
VYMI, the Vanguard International High Dividend Yield ETF, trades at $104.48, down slightly by 0.11% today. The technical outlook is bullish based on moving averages, with key support at $104 and resistance at $105. Recent news highlights strong institutional buying and its appeal to retirees seeking international dividend income, with the fund outperforming the S&P 500 over the past five years.
The ETF offers a compelling income play with a 3.4% dividend yield and an 8.86% five-year dividend CAGR, supported by bullish analyst sentiment. Risks include currency fluctuations from international exposure and broader market volatility, but its diversification and high yield provide a defensive stance amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →